Načítá se...
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis
Patients with end-stage renal disease present with a distinct challenge in oncology. Many anticancer drugs and their metabolites are excreted by the kidney, but data to guide dose and schedule adjustments in renal dialysis are scant. Pembrolizumab is an anti-programmed cell death protein 1 monoclona...
Uloženo v:
| Vydáno v: | BMJ Case Rep |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5051445/ https://ncbi.nlm.nih.gov/pubmed/27659911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-216426 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|